Ruigang Cai
机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, National Cancer Center
发表论文 5 篇 · 总被引 4 次 · h-index 1
代表论文
- Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial (2025 · The Breast · 被引 3)
- Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis (2025 · Therapeutic Advances in Medical Oncology · 被引 1)
- Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation (2025 · Future Oncology)
- Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy (2022 · Research Square)
- Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: Real-world data in the Han population (2020)